We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

MPARK:BISTMLP Saglik Hizmetleri AS Class B Analysis

Data as of 2026-06-15 - not real-time

TRY 450.75

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

MPARK trades with a clear valuation discount relative to its industry peers, as its trailing PE sits well below the sector average and the forward PE points to accelerating earnings, supporting a sizable upside potential. Profitability is solid, highlighted by operating margins in the mid‑teens and a ROE comfortably above twenty percent, while the balance sheet shows a moderate debt‑to‑equity ratio that provides financial flexibility. Revenue is expanding at a modest single‑digit rate and the forward EPS outlook more than doubles the trailing figure, underscoring a growth narrative, though the company does not pay a dividend, so investors must rely on price appreciation.
Technical indicators present a mixed picture: the 20‑day SMA hovers just above the current price and the 50‑day SMA remains slightly higher, indicating limited short‑term momentum. The RSI sits near the neutral zone, while a negative MACD histogram hints at bearish pressure. Volume has been rising, supporting a move toward identified resistance, yet the stock stays above its primary support, offering a cushion. Elevated volatility amplifies price swings, but a low beta suggests limited systematic risk, though Turkish macro‑economic factors add geographic and currency considerations. Overall, the blend of attractive valuation and growth prospects outweighs the short‑term technical softness.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • bearish MACD histogram
  • price near resistance with limited upside
  • elevated volatility

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • undervalued relative to peers
  • forward earnings acceleration
  • increasing trading volume

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • strong ROE and profit margins
  • expanding healthcare network
  • demographic tailwinds in Turkey

Key Metrics & Analysis

Financial Health

Revenue Growth5.70%
Profit Margin10.05%
P/E Ratio15.2
ROE20.55%
ROA10.26%
Debt/Equity49.96
P/B Ratio2.2
Op. Cash FlowTRY11.3B
Free Cash FlowTRY290.0M
Industry P/E24.6

Technical Analysis

TrendNeutral
RSI48.1
SupportTRY 434.75
ResistanceTRY 486.75
MA 20TRY 454.18
MA 50TRY 455.03
MA 200TRY 400.07
MACDBearish
VolumeIncreasing
Fear & Greed Index92.27

Valuation

Target PriceTRY 577.66
Upside/Downside28.15%
GradeUndervalued
TypeBlend

Risk Assessment

Beta0.38
Volatility43.28%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.